BioPharma Dive November 7, 2025
Skyrocketing healthcare costs could deliver another blow to the industry’s ongoing quest to boost representation in R&D.
Despite the lip service pharma companies have given to diversity, many studies are still failing to hit participation targets. Just 24% of clinical trial professionals said in a recent survey that their companies are currently benchmarking disease demographics against enrolled populations.
“Because [trial diversity] was important, [companies] were highlighting that they were going to do that. But did they have the data to show they were achieving it?” said Katrina Rice, the chief delivery officer at eClinical Solutions, a clinical data software and biometric services provider. “There was already a lot of room for growth.”
Now, a new challenge is ahead. Healthcare costs...
Today's Sponsors
Today's Sponsor